Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
6. |
ECCT/25/04/01 | PHASE 2/3 OF SII-TCV(B) A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS |
Principal Investigator(s) 1. WALTER OTIENO Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
View |
7. |
ECCT/25/03/07 | Sparkle - Site 1405 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Prof Videlis Nduba Site(s) in Kenya 1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. Gertrudes Children’s Hospital (Nairobi City county) 6. Victoria Biomedical Research Institute (Kisumu county) |
View |
8. |
ECCT/25/03/04 | Ndovu RCT Investigating the optimal management of dolutegravir resistance: an open-label randomised controlled trial of maintaining dolutegravir or switch to ritonavir-boosted darunavir |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kenyatta National Hospital (KNH) (Nairobi City county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 3. Bomu Hospital (Mombasa county) |
View |
9. |
ECCT/25/03/03 | ALIM STUDY Evaluating the safety and efficacy of Imatinib in combination with Artemether and Lumefantrine for the treatment of Uncomplicated Malaria: a three-part trial. |
Principal Investigator(s) 1. Dr. QUENTIN AWORI Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
View |
10. |
ECCT/25/03/01 | MK-5684_MSD (mCRPC) A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) |
Principal Investigator(s) 1. PROF MANSOOR NOORALI SALEH Site(s) in Kenya AGA KHAN UNIVERSITY HOSPITAL NAIROBI |
View |